GINZA NOA CLINIC
Tokyo, Japan International Patient Support
Contact Us

What Records Does a Stem Cell Clinic Need?

A stem cell clinic needs the records used to assess a patient and the records documenting any care it provides. These include diagnosis reports, relevant scans and laboratory results, medicines and allergies, treatment history, the physician’s assessment, informed consent, cell-product traceability, procedure notes, and follow-up and adverse-event records. The clinic also needs appropriate quality, regulatory, and data-protection documentation. What is legally required depends on the country, the product, and the procedure.

Patients supply their existing medical information. The clinic and its processing partners create the treatment and quality records; patients should not have to reconstruct that paperwork themselves.

What Records Does a Stem Cell Clinic Need?

This is general information, not medical advice or a complete legal compliance checklist. A qualified physician must assess whether a particular intervention is appropriate. Complete paperwork does not establish that a treatment is safe or effective for your condition.

The Records at a Glance

Record set What it should cover Who supplies or creates it
Medical intake Diagnosis, relevant specialist reports, imaging, laboratory results, medicines, allergies, prior treatment, and current function The patient and existing care team; the clinic records its review
Assessment and consent Eligibility decision, alternatives, proposed intervention, evidence, risks, costs, and documented consent The treating team, with the patient’s participation
Procedure and traceability Cell source, product identifier, processing and release records, administration details, and deviations The clinic and relevant processing facility
Follow-up and safety Review schedule, baseline and follow-up measures, new symptoms, adverse events, and actions taken The clinic, using patient reports and clinical assessments
Governance and privacy Applicable regulatory documents, quality responsibilities, access controls, retention arrangements, and permitted data sharing The clinic and relevant service providers

Records the Clinic Must Create

When assessing a clinic’s record-keeping, ask whether its notes explain what was reviewed, recommended, agreed, and done. The following is a practical checklist; it does not mean every item is a statutory requirement in every country.

Assessment and Informed Consent

The assessment should identify the physician, the records reviewed, the diagnosis and stage, relevant health conditions, and the reasons for offering, postponing, or declining treatment. It should also record missing information, further tests, and alternatives discussed.

Consent should cover the proposed cell or tissue source, collection and administration methods, the evidence and uncertainty for the patient’s condition, common and serious risks, alternatives, follow-up, and what happens if the patient declines. Costs and what they include should be clear before agreement. In Japan, Article 14 of the Act on the Safety of Regenerative Medicine requires appropriate explanation and consent for care within its scope, subject to specified exceptions.425AC0000000085

Ask for information in a language you understand and time to ask questions. Keep a copy of the consent documents. A signature alone is not a substitute for an explanation.

Procedure and Cell-Product Records

The treatment plan describes what is intended; the procedure note records what actually happened. Together, they should identify:

  • The date, time, place, and responsible clinicians
  • The cell or tissue source, including whether it is the patient’s own material or donor-derived
  • The relevant product or batch identifier and the cell processing facility
  • The preparation administered, amount or dose as applicable, administration route, and treatment site
  • Relevant observations, any departure from the plan, and the reason for it
  • Discharge instructions, follow-up arrangements, and urgent-contact details

Article 16 of Japan’s Act requires a record of the date and time, place, treatment details, and other prescribed matters, with preservation by the institution’s administrator. It is not enough to describe the procedure only as a “stem cell injection.”425AC0000000085

Traceability and Quality

The clinical note should connect to the records held by the processing facility. Ask how the material is identified through collection, processing, storage, transport, and administration, and where applicable testing and release decisions are documented. A patient-facing summary need not contain another person’s identifiable donor information.

In the United States, 21 CFR 1271.55 specifies that, once a donor-eligibility determination has been made, the human cell or tissue product must be accompanied by an identification code, a statement of donor eligibility or ineligibility, and a summary of the supporting records. The section also sets a retention period of at least 10 years after administration; if that date is unknown, the period runs from distribution, disposition, or expiration, whichever is latest.Subpart C

Do not apply that donor-eligibility checklist to every procedure without checking its scope. Section 1271.90 provides exceptions, including for cells and tissues intended for autologous use, meaning use in the same person. That exception does not by itself establish an exemption from every other applicable requirement.Subpart C

Evidence and Regulatory Status

The assessment should distinguish an approved product for a specific indication from an experimental intervention or a private-clinic service. Approval of one cell product does not establish approval of a different preparation or use.

For example, the FDA approved Ryoncil, a donor bone marrow-derived mesenchymal stromal cell therapy, on 18 December 2024 for steroid-refractory acute graft-versus-host disease in pediatric patients aged 2 months and older. This is a specific product and indication, not a general approval for clinic-marketed stem cell treatments.Fda approves first mesenchymal stromal cell therapy treat steroid refractory acute graft versus host

In Japan, the provision-plan process involves committee review and submission under Article 4. Filing a plan is not proof of clinical benefit or product marketing approval.425AC0000000085 The FDA also cautions that listing on ClinicalTrials.gov or registration with the FDA does not mean a product is legally marketed. A research registration is not evidence that a treatment works.Important patient and consumer information about regenerative medicine therapies

Follow-up and Adverse Events

The clinic should document what will be measured before and after treatment, when reviews are due, who assesses new symptoms, and how to contact the team after returning home. A useful adverse-event record includes onset, severity, assessment, treatment, outcome, and any required safety reporting.

The FDA has reported serious harms associated with unapproved regenerative products, including infections, blindness, and tumor formation.Important patient and consumer information about regenerative medicine therapies Japan’s Article 17 requires reporting to the designated certified committee when an institution learns of suspected treatment-related disease, disability, death, or infection, as provided by the rules.425AC0000000085

Ask for instructions about fever, severe pain, swelling, redness, or other new symptoms. Chest pain, severe shortness of breath, or sudden neurological changes need urgent medical assessment; do not wait for a message from an overseas clinic before seeking emergency care.

No responsible clinic can guarantee that a regenerative intervention will work.

Medical Records Patients Provide

Send records relevant to the condition under review, not an unsorted lifetime file. Confirm the clinic’s requirements before ordering tests or arranging travel. The physician may need an examination and additional investigations even after reviewing the file.

Diagnosis and Treatment History

Include the specialist report supporting the diagnosis and any relevant discharge summary, pathology report, biopsy result, or disease-specific test. Add previous treatments, surgeries, benefits, complications, and reasons treatments were stopped.

A one- to two-page summary can serve as a cover sheet, not a replacement for original reports. This is preparation guidance, not a national standard. Include the diagnosis and date, symptom changes, major illnesses, current limitations, and what you hope to improve. Attach a referral letter if you have one.

Imaging

Where imaging is relevant, ask whether the physician needs both the radiology report and the original DICOM image files. Screenshots or phone photos may omit parts of the study needed for review. Keep relevant older studies for comparison.

Label each study with the body part, side, and date performed. For example, “Right knee MRI, performed 12 May 2026” identifies the study more clearly than “latest scan.” The date of translation or upload is not the scan date.

Labs, Medicines, and Allergies

Send complete relevant laboratory reports, including the collection date, result, units, and reference range. The physician decides whether updated blood counts, infection screening, kidney or liver tests, or other investigations are needed for the proposed procedure.

List current prescriptions, doses, relevant over-the-counter medicines and supplements, and allergies with the reaction experienced. Include recent infections, hospital stays, and other safety information requested by the clinic. Do not stop a prescribed medicine simply to prepare a record packet; ask your treating physician about any proposed changes.

Function and Daily Life

Describe what the condition affects: walking distance, stairs, sleep, work, dressing, or the need for another person’s help. Send any function score already measured by your care team. Do not invent a score from memory.

A Practical File-Preparation Example

Suppose you have an imaging report, an image folder, and a laboratory PDF. This is an illustrative preparation example, not a patient case or a report of treatment experience.

  • Check that the imaging report and image folder refer to the same patient, body part, side, and examination date.
  • Keep the laboratory PDF intact. If you also make a summary, retain the original units and reference ranges rather than copying a number alone.
  • Attach the original report to any translation. If the documents appear to conflict, ask the issuing service to clarify rather than changing the original yourself.
  • Ask the receiving clinic to confirm that it can open the files and identify what is still missing.

These checks make the packet easier to verify. They do not show that the patient is eligible or that the proposed treatment is effective.

How Recent Should Records Be?

There is no single freshness rule for every diagnosis or procedure. Update medicines, allergies, and symptoms when you send the file. Tell the clinic about a new infection, surgery, hospitalization, or change in health after submission.

An older biopsy or operation report may remain important, while a pre-procedure safety test may need repeating. Ask the physician which records need updating and why. Do not assume that a recent upload date makes an old examination current.

Privacy, Storage, and Copies

Before sending sensitive files, confirm how your medical information will be handled. Ask:

  • Which information is needed and for what purpose?
  • Who can access it, including coordinators, laboratories, and processing facilities?
  • Will it be transferred across borders, and what safeguards and legal basis apply?
  • How long are the different record types retained?
  • How can you request a copy or correction, and who handles privacy questions?

Use an agreed secure submission method. Keep copies of what you send and receive. Before leaving after care, request your consent documents, procedure summary, follow-up plan, and urgent-contact details. Ask which additional information your home-country physician may need. Access to full processing or donor records may be restricted; ask for an appropriate coded summary rather than another person’s private information.

What to Confirm Before Proceeding

Ask the clinic who reviews your file, what is still missing, and whether the assessment is preliminary or requires an in-person visit. Confirm that you will receive a written explanation of the proposed intervention, its regulatory status, its risks, and the follow-up arrangements before deciding.

The essential record trail is straightforward: the information supporting the diagnosis, the reason for the treatment decision, informed consent, an identifiable product and documented procedure, and a plan for follow-up and problems. If the clinic cannot explain key gaps or will not document the proposed care, pause and seek independent medical advice. A complete file supports an informed decision; it is not a guarantee of benefit.

Sources

  1. [1] Japan, Act on the Safety of Regenerative Medicine, e-Gov, Japanese statutory text. Articles 4, 14, 16, and 17 cover provision plans, explanation and consent, treatment records, and committee reporting. Applies to care within the Act’s scope. Accessed 1 November 2026.
  2. [2] United States, 21 CFR Part 1271, Subpart C, eCFR. Section 1271.55 addresses accompanying donor-eligibility records and retention; Section 1271.90 provides exceptions, including autologous use. These are not universal rules for all clinic records. Accessed 1 November 2026.
  3. [3] FDA approval announcement for Ryoncil, 18 December 2024. United States; the named product for steroid-refractory acute graft-versus-host disease in pediatric patients aged 2 months and older. Accessed 1 November 2026.
  4. [4] FDA, Important Patient and Consumer Information About Regenerative Medicine Therapies, dated 3 June 2021. Used here for reported harms and the distinction between registration and legal marketing, not as a current exhaustive list of approved products. United States. Accessed 1 November 2026.

Not sure which records to prepare?

Ask about the records needed for an initial consultation and how to submit them securely. A consultation does not guarantee treatment eligibility or benefit.

Ask about record requirements